63.13
-0.61
(-0.96%)
After Hours: 63.13
0.00
(0.00%)
May 17, 4:11PM EDT
OTCMKTS
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | 62.56 - 63.33 |
| 52 week | 38.63 - 64.48 |
| Open | 62.85 |
| Vol / Avg. | 327,138.00/455,607.00 |
| Mkt cap | 217.81B |
| P/E | 21.84 |
| Div/yield | 2.02/3.20 |
| EPS | 2.89 |
| Shares | 3.45B |
| Beta | 0.69 |
| Inst. own | 1% |
Events
Jul 25, 2013
Half Year 2013 Roche Holding AG Earnings Conference Call
Jul 25, 2013
Half Year 2013 Roche Holding AG Earnings Release
Jun 24, 2013
Roche Holding AG at JP Morgan Health Conference
Jun 20, 2013
Roche Holding AG at Barclays West Coast Investor Conference
Jun 18, 2013
Roche Holding AG at DVFA Life Sciences Conference
Jun 13, 2013
Roche Holding AG at Goldman Sachs Healthcare Conference
Jun 11, 2013
Roche Holding AG at Vontobel Summer Conference
Jun 4, 2013
Roche Holding AG at Jefferies Global Healthcare Conference
Jun 2, 2013
Roche Holding AG Analyst Event at ASCO 2013
- 7:30PM EDT -
May 30, 2013
Roche Holding AG at JP Morgan, COO Conference Call Series
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | 23.42% | 21.48% |
| Operating margin | 33.68% | 30.99% |
| EBITD margin | - | 41.87% |
| Return on average assets | 17.33% | 15.47% |
| Return on average equity | 87.43% | 71.75% |
| Employees | 82,089 | - |
| Carbon Disclosure Rating | - | 75/100 |
Address
Grenzacherstrasse 124
Basel, 4070
Switzerland
+41-9-732354295 (Phone)
Basel, 4070
Switzerland
+41-9-732354295 (Phone)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Roche Holding AG is a Swiss pharmaceuticals and diagnostics holding company. It belongs to the Roche Group that operates through subsidiaries and associated companies around the world. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. The Company has two divisions: Pharmaceuticals and Diagnostics. Pharmaceuticals are divided into two sub-divisions: Roche Pharmaceuticals and Chugai. It operates in the United States, Western Europe, Japan, CEMAI (Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent), Latin America, Asia-Pacific and Other regions. Diagnostics include five business areas: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. It operates in five geographical regions: Europe, Middle East and Africa (EMEA); North America; Asia-Pacific; Latin America, and Japan.
Officers and directors
| Severin Schwan | Chairman of the Corporate Executive Committee, Chief Executive Officer | |
| Alan Hippe | Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer | |
| Stephan Feldhaus | Member of the Enlarged Corporate Executive Committee, Head Group Communications | |
| Sophie Kornowski-Bonnet | Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | |
| Osamu Nagayama | Member of the Enlarged Corporate Executive Committee, President and Chief Executive Officer of Chugai | |
| John C. Reed M.D., Ph.D. | Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | |
| Richard H. Scheller | Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | |
| Urs Jaisli | Chief Compliance Officer | |
| Gottlieb A. Keller | Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors | |
| Silvia Ayyoubi | Member of the Corporate Executive Committee, Head of Group Human Resources |
